Prenatal CFTR modulator therapy for fetal cystic fibrosis: Emerging evidence, clinical considerations, and future directions

Abstract Background The consequences of cystic fibrosis (CF) transmembrane conductance regulator (CFTR) protein dysfunction or absence begin during fetal development, with pancreatic, intestinal, hepatobiliary, and reproductive manifestations evident at birth. The advent of CFTR modulator therapies...

Celý popis

Podrobná bibliografie

Hlavní autoři:	Hiba J. Mustafa, Yair J. Blumenfeld, Ramen H. Chmait, Jennifer L. Taylor‐Cousar, Jordana E. Hoppe, Stacey L. Martiniano, Angela Metcalf, Scott D. Sagel, Edith T. Zemanick, Alireza A. Shamshirsaz, Sylvia E. Szentpetery, Aaron T. Trimble, Elizabeth B. Burgener, Carmen Luna‐Paredes, Isabelle Sermet‐Gaudelus, Michael V. Zaretsky
Médium:	Artigo
Jazyk:	Inglês
Vydáno:	Wiley 2026-07-01
Edice:	Pregnancy
Témata:	CFTR cystic fibrosis ETI fetal therapy meconium ileus modulator therapy
On-line přístup:	https://doi.org/10.1002/pmf2.70317
Tagy:	Přidat tag Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!